Urinary Incontinence (Adult)

1. Clinical Overview

Definition and Significance

Urinary Incontinence (UI) is defined by the International Continence Society as "the complaint of involuntary loss of urine." [1] It represents a major public health issue affecting millions of individuals worldwide, with profound impact on quality of life, social functioning, psychological wellbeing, and healthcare costs. UI is not a disease per se, but a symptom complex arising from diverse underlying pathophysiological mechanisms affecting the lower urinary tract. [2]

The condition is significantly underreported due to social stigma, with many patients considering it an inevitable part of aging rather than a treatable medical condition. [3] The economic burden is substantial, with annual costs in the United States alone exceeding $19 billion when accounting for direct medical costs, nursing home admissions, and productivity losses. [4]

Understanding urinary incontinence requires appreciation of its heterogeneous nature. The International Continence Society classifies UI into several distinct subtypes based on symptoms, urodynamic findings, and underlying pathophysiology. The main categories include Stress Urinary Incontinence (SUI), Urgency Urinary Incontinence (UUI), Mixed Urinary Incontinence (MUI), Overflow Incontinence, and Functional Incontinence. Each subtype has distinct mechanisms, risk factors, and management approaches. [1,2]

Clinical Relevance

UI is a high-yield topic for multiple postgraduate examinations including MRCOG, MRCP (Geriatrics), FRCS (Urology), and general practice assessments. It exemplifies the integration of anatomy, physiology, pharmacology, and surgical techniques. Examination scenarios frequently test candidates on:

• Differentiation between stress and urge incontinence based on history
• Interpretation of bladder diaries and urodynamic studies
• Evidence-based management algorithms
• Pharmacological mechanisms (anticholinergics, beta-3 agonists, duloxetine)
• Surgical options and the contemporary mesh controversy
• Management in special populations (elderly, neurogenic bladder)

Key Clinical Pearls

The "Key in the Door" Sign: Pathognomonic for urgency urinary incontinence. Patients describe a sudden overwhelming urge to void upon arriving home, often triggered by the sound of keys or running water—a conditioned reflex demonstrating the bladder's learned response to environmental cues. [5]

Caffeine: Double Trouble: Acts both as a diuretic (increasing urine production) and as a direct bladder irritant stimulating detrusor muscle contractions. Caffeine reduction is often the single most effective lifestyle intervention for overactive bladder syndrome. [6]

UTI Mimicry: Urinary tract infection can perfectly mimic urgency incontinence with frequency, urgency, and urge leaks. ALWAYS perform urinalysis before initiating antimuscarinic therapy. Starting anticholinergics in the presence of infection risks urinary retention. [7]

Estrogen Deficiency and the Genitourinary Syndrome of Menopause: Postmenopausal estrogen deficiency causes vaginal and urethral atrophy, contributing significantly to urgency, frequency, and recurrent UTIs. Topical vaginal estrogen is safe and effective, even in women with contraindications to systemic hormone therapy. [8]

Postpartum Incontinence Resolution: Approximately 50-70% of pregnancy-related stress urinary incontinence resolves spontaneously within 12 months postpartum. However, conservative interventions including supervised pelvic floor muscle training initiated early postpartum significantly improve resolution rates and should be offered to all symptomatic women. [37]

---

Epidemiology

Prevalence and Incidence

Urinary incontinence affects approximately 200-423 million people globally, representing one of the most common chronic conditions worldwide. [9] A recent systematic review and meta-analysis estimated that urinary incontinence affects up to 50% of adult women at some point in their lifetime, with significant variations based on population demographics and definitions used. [31] Prevalence varies substantially by population, age, sex, and definition used in epidemiological studies.

Annual incidence rates range from 2-11% in community-dwelling adults, with higher rates in women, the elderly, and those with predisposing comorbidities. [15] Importantly, UI demonstrates a bimodal distribution in women, with peaks during reproductive years (associated with pregnancy and childbirth) and in the postmenopausal period. [10]

Subtype Distribution

Among incontinent individuals:

• Stress Urinary Incontinence (SUI): 24-45% of cases
• Urgency Urinary Incontinence (UUI): 21-40% of cases
• Mixed Urinary Incontinence (MUI): 30-35% of cases
• Overflow and Other: 5-10% of cases [2,10]

The relative proportion shifts with age: younger women predominantly experience SUI, while UUI becomes more prevalent in older populations. Men more commonly present with UUI and overflow incontinence, particularly in the context of benign prostatic hyperplasia. [12,13]

Risk Factors

Non-Modifiable Risk Factors

Age: The single strongest predictor of UI prevalence. Each decade of life after age 40 increases the odds of UI by approximately 20-30%. [14] Aging is associated with:

• Reduced bladder capacity
• Decreased urethral closure pressure
• Increased detrusor overactivity
• Increased post-void residual volumes
• Accumulation of comorbidities affecting continence

Female Sex: Women are 2-3 times more likely to experience UI than age-matched men, primarily due to:

• Anatomical differences (shorter urethra, lack of prostatic support)
• Effects of pregnancy and vaginal childbirth on pelvic floor integrity
• Hormonal changes during menopause affecting urogenital tissues [10,11]

Genetic Predisposition: Family history of UI increases risk by 1.5-2 fold, suggesting heritable factors affecting connective tissue strength and pelvic floor muscle function. [16]

Ethnicity: White and Hispanic women report higher UI prevalence than African-American or Asian women in population studies, though reasons remain unclear and may reflect differences in help-seeking behavior, pelvic anatomy, or connective tissue properties. [10]

Modifiable Risk Factors

Obesity: Body Mass Index (BMI) > 30 kg/m² increases UI risk by 2-3 fold, particularly for SUI. [17] Mechanisms include:

• Chronic increased intra-abdominal pressure
• Mechanical stress on pelvic floor musculature
• Metabolic factors (insulin resistance, inflammation)
• Weight loss of 5-10% can reduce UI episodes by 40-60% [17]

Pregnancy and Childbirth:

• Pregnancy itself increases UI risk (hormonal effects, mechanical pressure)
• Vaginal delivery increases SUI risk 2-3 fold compared to nulliparous women [10]
• Instrumental delivery (forceps, ventouse) further increases risk
• Cesarean section reduces but does not eliminate risk
• Cumulative effect: each additional vaginal delivery increases odds by ~10-20%

Smoking: Increases UI risk by 1.5-2 fold through multiple mechanisms: [18]

• Chronic cough increasing intra-abdominal pressure
• Nicotine effects on bladder contractility
• Impaired collagen synthesis affecting pelvic support
• Bladder irritation from urinary metabolites

Occupation and Physical Activity: Heavy lifting occupations and high-impact sports (running, gymnastics, trampolining) increase SUI risk in women. [19]

\u003cExamDetail\u003e

Exercise-Induced Urinary Incontinence (EIUI): A specific subset of SUI occurring during physical exercise, affecting 20-50% of female athletes depending on sport type. [38] High-impact activities (running, jumping sports, gymnastics, CrossFit) generate intra-abdominal pressures exceeding 150 cmH₂O, substantially greater than daily activities.

Management Strategies for EIUI:

• Pelvic Floor Muscle Training: First-line. Pre-exercise pelvic floor contraction ("the Knack") immediately before high-impact maneuvers reduces leak episodes by 70-80%. [38]
• Bladder Emptying Pre-Exercise: Reduces leak volume
• Pessary Use: Continence pessaries worn during exercise sessions provide mechanical support
• Sport Modification: Temporarily reducing impact intensity during PFMT strengthening phase
• Reframing Expectations: EIUI is common but NOT normal. Women should be encouraged to seek treatment rather than accept leakage as "part of being an athlete."

A 2024 systematic review of conservative interventions for female exercise-induced UI confirmed that supervised PFMT, with or without biofeedback, demonstrates moderate-to-high quality evidence for reducing EIUI episodes and improving quality of life in active women. [38]

\u003c/ExamDetail\u003e

Medications:

• Diuretics: Increase urine production and urgency
• Anticholinesterases: Increase detrusor tone
• Alpha-adrenergic blockers: Reduce urethral tone (men)
• Sedatives/hypnotics: Impair awareness and mobility (functional incontinence)

Medical Comorbidities

Neurological Conditions:

• Stroke: 40-60% develop UI acutely; 25% have persistent incontinence [7]
• Multiple Sclerosis: 50-80% experience UI (detrusor hyperreflexia, sphincter dyssynergia)
• Parkinson's Disease: 40-70% develop UUI (dopaminergic control of micturition)
• Spinal cord injury: Varies by level and completeness of injury
• Dementia: Progressive loss of cortical inhibition of micturition reflex

Diabetes Mellitus: 2-fold increased risk through multiple mechanisms: [7]

• Osmotic diuresis (hyperglycemia)
• Diabetic cystopathy (detrusor underactivity, overflow incontinence)
• Peripheral and autonomic neuropathy
• Increased UTI risk

Pelvic Pathology:

• Pelvic organ prolapse (60-80% association with SUI)
• Previous pelvic surgery (hysterectomy, prostatectomy)
• Pelvic radiation therapy
• Constipation and fecal impaction (particularly in elderly)

---

3. Aetiology and Pathophysiology

Normal Continence Mechanism

Maintenance of urinary continence requires coordinated function of the bladder, urethra, pelvic floor musculature, and neural control pathways. During the storage phase:

1. Bladder (Detrusor Muscle): Remains relaxed (sympathetic beta-3 adrenergic stimulation)
2. Bladder Neck and Proximal Urethra: Remain closed (sympathetic alpha-1 adrenergic stimulation)
3. External Urethral Sphincter: Contracts voluntarily (somatic pudendal nerve, S2-S4)
4. Pelvic Floor Muscles: Provide support, maintain urethral position
5. Cortical Centers: Suppress parasympathetic voiding reflex

Urethral closure pressure must exceed intravesical pressure throughout the storage phase. Normal urethral closure pressure in women is 60-100 cmH₂O; in men 80-120 cmH₂O (augmented by prostatic compression). [1,2]

Stress Urinary Incontinence (SUI): Pathophysiology

SUI occurs when increased intra-abdominal pressure (coughing, sneezing, laughing, physical exertion) is transmitted to the bladder but not equally to the urethra, resulting in intravesical pressure exceeding urethral closure pressure. Two primary mechanisms have been identified:

Urethral Hypermobility (80-90% of SUI cases)

Anatomical Basis: Weakness or damage to the endopelvic fascia (pubocervical fascia) and levator ani muscles results in descent of the bladder neck and proximal urethra below the pelvic floor during increased intra-abdominal pressure. [20]

Consequences:

• Loss of pressure transmission to proximal urethra
• Opening of bladder neck during cough/strain
• Altered urethrovesical angle (normally 90-100°)

Risk Factors: Vaginal childbirth (particularly operative delivery), chronic increased intra-abdominal pressure (obesity, chronic cough), aging, estrogen deficiency, connective tissue disorders.

Intrinsic Sphincter Deficiency (ISD) (10-20% of SUI cases)

Pathophysiology: The urethral sphincter mechanism itself is weakened or damaged, causing inadequate coaptation even at rest. The urethra cannot maintain closure under stress regardless of anatomical position. [20]

Causes:

• Neurological injury (sacral nerve damage, spinal cord lesions)
• Direct sphincter trauma (childbirth, pelvic surgery, radiation)
• Severe estrogen deficiency (mucosal thinning, reduced vascularity)
• Aging (reduced smooth and striated muscle mass)
• Prior anti-incontinence surgery (over-correction, erosion)

Clinical Significance: ISD is associated with lower success rates for standard surgical procedures. Urodynamic assessment (low Valsalva leak point pressure less than 60 cmH₂O or low maximal urethral closure pressure less than 20 cmH₂O) helps identify ISD. [20]

Exam Detail: Molecular Mechanisms in SUI Development:

The pelvic floor connective tissue matrix consists predominantly of Type I and Type III collagen, providing structural support. Studies have demonstrated:

• Altered Collagen Ratios: Women with SUI show decreased Type I:Type III collagen ratio in pubocervical fascia, resulting in reduced tensile strength [16]
• Matrix Metalloproteinase (MMP) Dysregulation: Increased MMP-1 and MMP-9 activity accelerates collagen degradation [16]
• Estrogen Effects: Estrogen receptors (ERα and ERβ) are present throughout the lower urinary tract. Estrogen maintains:
  • Collagen synthesis and organization
  • Urethral vascularity and mucosal thickness
  • Alpha-adrenergic receptor density
  • Estrogen deficiency reduces these parameters [8]
• Genetic Factors: Polymorphisms in collagen genes (COL1A1, COL3A1) and MMP genes associate with increased SUI susceptibility [16]

Urgency Urinary Incontinence (UUI): Pathophysiology

UUI results from detrusor overactivity (DO), defined urodynamically as involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked. [1] These contractions generate sufficient pressure to overcome urethral resistance.

Neurogenic Detrusor Overactivity

Results from loss of cortical inhibition or spinal reflex dysregulation:

Suprapontine Lesions (Stroke, Parkinson's, Dementia):

• Loss of cortical inhibition of pontine micturition center
• Preserved bladder-sphincter coordination
• Urodynamics: Detrusor overactivity with coordinated sphincter

Suprasacral Spinal Lesions (Spinal cord injury, Multiple Sclerosis):

• Loss of cortical control
• Disrupted coordination (detrusor-sphincter dyssynergia)
• Urodynamics: Detrusor overactivity with elevated voiding pressures
• Risk of upper tract damage (vesicoureteral reflux, hydronephrosis)

Idiopathic Detrusor Overactivity

The majority of UUI cases have no identifiable neurological cause. Proposed mechanisms include:

Myogenic Theory:

• Increased detrusor smooth muscle excitability
• Enhanced spontaneous contractile activity
• Increased intercellular coupling (gap junctions) propagating contractions
• Altered expression of calcium channels and receptors [5]

Urothelial Theory:

• The urothelium acts as a sensory structure, releasing transmitters (ATP, acetylcholine, prostaglandins)
• Bladder afferent hypersensitivity triggers premature voiding reflex
• Increased suburothelial nerve density observed in OAB patients [5]

Aging-Related Changes:

• Ischemia from vascular disease reduces bladder compliance
• Decreased β₃-adrenoreceptor density impairs relaxation
• Increased cholinergic receptor sensitivity

Exam Detail: Neurotransmitter Systems in Bladder Control:

Storage Phase (Bladder Relaxation):

• Sympathetic (T10-L2 via hypogastric nerve):
  • β₃-adrenoreceptors on detrusor → relaxation (primary)
  • α₁-adrenoreceptors on bladder neck/urethra → contraction/closure
• Somatic (S2-S4 via pudendal nerve):
  • Nicotinic receptors on external sphincter → voluntary contraction

Voiding Phase (Bladder Contraction):

• Parasympathetic (S2-S4 via pelvic nerve):
  • M₂ and M₃ muscarinic receptors on detrusor → contraction
  • M₃ primarily responsible for active contraction [5]

Pharmacological Targets:

• Anticholinergics: Block M₃ receptors → reduce detrusor contractions
• β₃-agonists (Mirabegron): Stimulate β₃ receptors → enhance bladder relaxation
• Duloxetine (SNRI): Increases serotonin/norepinephrine in Onuf's nucleus → enhanced sphincter contraction during storage [21]

Overflow Incontinence: Pathophysiology

Overflow incontinence occurs when the bladder becomes chronically overdistended due to either:

Bladder Outlet Obstruction (BOO)

Men: Benign prostatic hyperplasia (BPH) most common; also urethral stricture, prostate cancer Women: Less common; severe pelvic organ prolapse (urethral kinking), previous anti-incontinence surgery (over-correction)

Mechanism: Bladder fills beyond capacity; intravesical pressure eventually exceeds urethral resistance → continuous dribbling without complete emptying. [1]

Detrusor Underactivity / Acontractility

Neurological Causes:

• Diabetic cystopathy (autonomic neuropathy)
• Sacral spinal cord lesions
• Cauda equina syndrome
• Pelvic nerve injury (radical pelvic surgery)

Non-neurological Causes:

• Chronic overdistension (longstanding BOO causing detrusor decompensation)
• Aging (myogenic degeneration)
• Medications (anticholinergics, calcium channel blockers)

Mechanism: Impaired/absent detrusor contractility → incomplete emptying → progressive retention → overflow when capacity exceeded. [1]

Mixed Urinary Incontinence (MUI)

MUI involves coexistence of both SUI and UUI symptoms. Affects 30-35% of incontinent individuals, particularly older women. Pathophysiologically represents independent coexistence of urethral incompetence AND detrusor overactivity. Management challenges include determining which component is more bothersome to guide initial therapy. [2]

Functional Incontinence

Incontinence primarily due to factors external to the urinary tract:

• Cognitive impairment (dementia, delirium)
• Physical immobility (arthritis, stroke, Parkinson's)
• Environmental barriers (inaccessible toilets, restraints)
• Psychological factors (depression, motivation)

Common in frail elderly and nursing home populations. Bladder function may be normal, but patient cannot toilet in timely manner. [14]

---

4. Clinical Presentation

Symptom Patterns by Subtype

Accurate symptom characterization is essential for diagnosis and guides appropriate investigation and management.

Stress Urinary Incontinence (SUI)

Cardinal Symptom: Involuntary urine leakage occurring simultaneously with physical exertion, coughing, sneezing, or laughing. [1]

Typical Features:

• Leakage volume: Usually small to moderate ("squirt" or "splash")
• Predictable trigger: Specific activities (exercise, lifting, cough)
• No sensation of urgency preceding leak
• Rarely occurs at night or at rest
• Volume correlates with activity intensity
• Frequency: Usually normal (7-8 voids/24 hours)

Severity Grading (Ingelman-Sundberg classification):

• Grade I: Leakage with severe stress (coughing, sneezing)
• Grade II: Leakage with moderate stress (running, climbing stairs)
• Grade III: Leakage with minimal stress (standing, walking)

Impact on Daily Life:

• Avoidance of exercise and physical activities
• Wearing pads or protective garments
• Limiting fluid intake (counterproductive)
• Social embarrassment and withdrawal

Urgency Urinary Incontinence (UUI)

Cardinal Symptom: Involuntary urine leakage associated with, or immediately preceded by, a sudden compelling desire to void (urgency). [1]

Typical Features:

• Urgency: Sudden, difficult-to-defer urge (ICS definition: "complaint of sudden compelling desire to pass urine which is difficult to defer")
• Leakage volume: Moderate to large (may be complete bladder emptying)
• Warning time: Seconds to 1-2 minutes maximum
• Triggers: Environmental cues ("key in door"), running water, cold weather
• Frequency: Increased daytime voiding (> 8 voids/24 hours)
• Nocturia: Common (≥2 voids per night)
• May have urgency WITHOUT incontinence (Overactive Bladder Syndrome)

Overactive Bladder Syndrome (OAB): Defined as urgency with or without urge incontinence, usually with frequency and nocturia, in the absence of infection or other pathology. [2]

• OAB-dry: Urgency and frequency WITHOUT incontinence (50-60% of OAB)
• OAB-wet: Urgency WITH incontinence (40-50% of OAB)

Common Triggers:

• "Key in door syndrome" (conditioned reflex upon arriving home) [5]
• Hand washing or sound of running water
• Cold exposure
• Caffeinated beverages
• Alcohol consumption

Mixed Urinary Incontinence (MUI)

Combination of stress and urge symptoms. Patients report leakage with both exertion AND urgency. [2]

Clinical Importance:

• Determine which component is MORE bothersome (guides initial therapy)
• May require combined treatment strategies
• Often requires urodynamic assessment before surgery
• Stress component may unmask after successful UUI treatment (and vice versa)

Overflow Incontinence

Cardinal Features:

• Continuous or frequent dribbling
• Sensation of incomplete emptying
• Weak urinary stream
• Straining to void
• Paradoxical incontinence: Small frequent leaks despite rarely achieving complete void

Red Flags:

• Palpable or percussible bladder (chronic retention)
• Post-void residual > 300 mL
• Associated lower abdominal discomfort

In Men: Often accompanied by obstructive symptoms (hesitancy, poor stream, terminal dribbling) suggesting BPH

In Women: Less common; consider previous anti-incontinence surgery, severe prolapse, neurological disease

Functional Incontinence

Features:

• Awareness of need to void but unable to reach toilet in time
• Urinary symptoms may be normal
• Cognitive impairment, mobility issues, environmental barriers
• Common in institutionalized elderly

Differential Diagnosis of Incontinence Symptoms

Clinical History Taking: Key Questions

A structured approach to history is essential:

Urinary Symptom Characterization

1. Type of Leakage:

   • "Do you leak urine when you cough, sneeze, laugh, or exercise?" (SUI)
   • "Do you get a sudden urgent need to pass urine that is difficult to control?" (UUI)
   • "Do you leak on the way to the toilet?" (UUI)

2. Volume and Frequency:

   • "How much do you leak? A few drops, or enough to soak through clothing?"
   • "How many times do you pass urine during the day? During the night?"

3. Triggers and Patterns:

   • "What activities or situations make leakage more likely?"
   • "Do you leak standing up, or also when lying down?" (continuous leak suggests fistula)

4. Associated Symptoms:

   • Dysuria, haematuria (infection, malignancy)
   • Straining, weak stream, incomplete emptying (obstruction, retention)
   • Pelvic pain (interstitial cystitis, endometriosis)
   • Neurological symptoms (cord compression, MS)

Impact Assessment

• Quality of Life: "How much does this problem bother you?" (1-10 scale)
• Daily Activities: Impact on work, exercise, social activities
• Pad Usage: Number and type of pads per day (quantifies severity)
• Fluid Restriction: Many patients restrict intake (counterproductive)

Obstetric and Gynaecological History (Women)

• Parity: Number of pregnancies and mode of delivery (vaginal vs cesarean)
• Instrumental Delivery: Forceps, ventouse (increases SUI risk)
• Infant Birth Weight: Macrosomia (> 4 kg) increases risk
• Menopause Status: Age at menopause, hormone replacement therapy use
• Prolapse Symptoms: Sensation of bulge, pelvic pressure
• Previous Pelvic Surgery: Hysterectomy, prolapse repair, previous incontinence surgery

Urological and Surgical History (Men)

• Prostate Symptoms: Obstructive (hesitancy, weak stream) and irritative (frequency, urgency)
• Prostate Surgery: TURP, radical prostatectomy, brachytherapy
• PSA Testing: Previous results if known

Medical and Medication History

• Neurological Disease: Stroke, Parkinson's, MS, spinal injury, diabetes
• Mobility and Cognition: Impairments affecting toileting ability
• Medications:
  • Diuretics (time of dosing)
  • Anticholinergics, antihistamines (may worsen retention)
  • Alpha-blockers (may worsen SUI in men)
  • Antidepressants, sedatives (functional impairment)

Lifestyle Factors

• Smoking: Current, ex-smoker, pack-years (chronic cough)
• BMI / Weight Changes: Obesity is major modifiable risk factor
• Caffeine Intake: Coffee, tea, energy drinks (mL/day)
• Alcohol Consumption: Diuretic and irritant effects
• Fluid Intake: Total volume, timing (excessive intake or restriction)
• Physical Activity: Type and intensity (high-impact sports)

---

5. Clinical Examination

General and Systemic Assessment

Observations:

• Mobility: Gait, use of walking aids (functional impairment)
• Cognitive Function: Orientation, memory (functional component)
• BMI Calculation: Weight (kg) / Height² (m²)

Neurological Screening (if neurogenic etiology suspected):

• Lower Limb Neurology: Tone, power, reflexes, sensation
• Sacral Nerve Roots (S2-S4):
  • Perineal sensation
  • Anal sphincter tone (digital rectal exam)
  • Bulbocavernosus reflex (specialist assessment)
• Gait Assessment: Spasticity (upper motor neuron), ataxia (cerebellar, proprioceptive)

Abdominal Examination

Inspection:

• Surgical scars (previous abdominal/pelvic surgery)
• Distension (chronic retention, ascites)

Palpation:

• Bladder: Normally not palpable. Palpable/percussible bladder indicates retention (typically > 500 mL)
  • Palpable bladder + incontinence = Overflow incontinence (chronic retention)
  • Requires urgent post-void residual measurement
  • Do NOT start anticholinergics if retention suspected
• Masses (pelvic tumors, fibroids, ovarian cysts)
• Organomegaly, ascites

Red Flag: Palpable bladder in setting of incontinence mandates immediate assessment for chronic retention and consideration of catheterization.

Pelvic Examination (Women)

Essential component of assessment. Performed with patient consent, with chaperone.

Inspection

Vulva and Introitus:

• Atrophy: Pale, dry, smooth mucosa; loss of rugae; labial fusion (estrogen deficiency) [8]
• Dermatitis: Erythema, maceration, excoriation (incontinence-associated dermatitis)
• Leakage: Observe for spontaneous leakage at rest

Prolapse Assessment:

• Ask patient to strain/cough
• Anterior Vaginal Wall Prolapse (cystocele, urethrocele): Bulge from anterior wall
• Posterior Vaginal Wall Prolapse (rectocele, enterocele): Bulge from posterior wall
• Apical Prolapse (uterine, vault): Descent of cervix/vault
• Grade severity using POP-Q (Pelvic Organ Prolapse Quantification) system (specialist assessment)

Palpation and Functional Assessment

Bimanual Pelvic Examination:

• Uterine size, mobility (fibroids, masses)
• Adnexal masses (ovarian pathology)
• Pelvic tenderness (infection, endometriosis)

Cough Stress Test (Key SUI Diagnostic Maneuver): [1]

1. Ensure bladder is comfortably full (250-300 mL; patient may need to drink water and wait)
2. Patient in lithotomy position initially, then standing if negative
3. Insert speculum or place cotton swab at introitus
4. Ask patient to cough forcefully
5. Positive Test: Direct visualization of urine leakage from urethra simultaneous with cough
6. Interpretation:
   • Immediate leak with cough = SUI highly likely
   • Delayed leak (few seconds after cough) = may represent urgency triggered by cough
   • No leak = SUI less likely (but does not exclude if bladder insufficiently full)

Pelvic Floor Muscle Assessment (Modified Oxford Scale 0-5): [22]

Patient asked to contract pelvic floor ("squeeze and lift as if stopping urine flow"). Examiner assesses with two fingers in vagina:

• Assessment aids prognosis for pelvic floor muscle training (PFMT)
• Grade 0-2: Referral to specialist physiotherapist recommended
• Assess for "Valsalva instead of contract" (patient bears down instead of contracting—common error requiring retraining)

Digital Rectal Examination (DRE)

In Men:

• Prostate Size: Normal (~20 g, size of walnut), enlarged (BPH), hard/nodular (prostate cancer)
• Anal Sphincter Tone: Reduced tone suggests sacral nerve dysfunction
• Fecal impaction (can contribute to urinary retention and incontinence)

In Women (if posterior prolapse suspected):

• Rectocele Assessment: Palpate anterior rectal wall during strain
• Anal Tone: S2-S4 function

Post-Void Residual (PVR) Measurement

Method: Bladder ultrasound scan immediately after patient voids to completion.

Interpretation:

• less than 50 mL: Normal
• 50-100 mL: Borderline (repeat measurement)
• 100-200 mL: Mild incomplete emptying
• > 200 mL: Significant retention
• > 300 mL: Chronic retention (high risk for overflow incontinence)

Clinical Significance:

• Elevated PVR (> 100-150 mL) is relative contraindication to anticholinergic therapy (risk of acute retention)
• Guides need for further investigation (urodynamics) and management (intermittent self-catheterization)
• Identifies overflow incontinence

---

6. Investigations

First-Line Investigations (Primary Care)

Urinalysis and Urine Culture

Indications: All patients presenting with urinary incontinence.

Technique: Clean-catch midstream urine (MSU). Dipstick analysis followed by microscopy and culture if abnormal.

Interpretation:

• Leucocytes/Nitrites Positive: Urinary tract infection. Treat infection; reassess incontinence after treatment completion. UTI can mimic UUI perfectly. [7]
• Blood Positive: Requires further investigation (see below).
• Glucose Positive: Undiagnosed or poorly controlled diabetes. Check HbA1c.
• Protein Positive: Renal pathology; warrants nephrology assessment if persistent.

Haematuria Protocol:

• Visible Haematuria: Urgent urology referral (2-week wait pathway if ≥45 years) for cystoscopy and upper tract imaging (bladder cancer, stones, renal cancer) [23]
• Non-visible (Microscopic) Haematuria + Age ≥50: Urology referral
• Non-visible + Age less than 50 + Risk Factors (smoking, occupational exposure): Consider urology referral

Bladder Diary (Frequency-Volume Chart)

Gold Standard for Objective Assessment. [1,2]

Method: Patient records for minimum 3 consecutive days (ideally including weekend):

• Time of each void
• Volume of each void (measured in jug)
• Fluid intake (volume and type)
• Incontinence episodes (with description of circumstances)
• Pad usage
• Severity of urgency (optional: scale 0-5)

Parameters Derived:

Interpretation Examples:

Stress UI Pattern:

• Normal frequency (6-8 voids/day)
• Normal voided volumes (250-400 mL)
• Incontinence episodes recorded during exercise, coughing
• Minimal/no nocturia

Urge UI Pattern:

• Increased frequency (> 10 voids/day)
• Small voided volumes (less than 200 mL)
• Multiple urgency episodes
• Nocturia (2-4 voids/night)
• Incontinence often recorded with urgency notation

Overflow Pattern:

• Frequent small voids
• Low voided volumes (less than 100 mL)
• Continuous dribbling
• Sensation of incomplete emptying

Excessive Fluid Intake:

• Total intake > 3000 mL/day (> 4000 mL if large caffeine/alcohol component)
• Normal voided volumes but excessive frequency
• Patient education regarding appropriate intake

Post-Void Residual (PVR) Ultrasound

Discussed above (Examination section). Perform immediately after void. > 100 mL warrants further assessment; > 200 mL significant.

Second-Line Investigations (Specialist)

Referral to Urogynaecology or Urology indicated when:

• Diagnosis uncertain after initial assessment
• Failed conservative management (lifestyle + first-line therapy)
• Considering surgical intervention (urodynamics mandatory before surgery)
• Complicated incontinence (recurrent, post-surgical, neurogenic, coexistent prolapse)
• Haematuria (visible or non-visible with risk factors)
• Pelvic mass or suspected malignancy
• Elevated post-void residual (> 200 mL) or suspected retention

Urodynamic Studies (Cystometry)

Indications (NICE NG123): [1]

• Prior to surgical intervention for SUI (ESSENTIAL—to confirm diagnosis and predict outcomes)
• UUI not responding to first-line therapies
• Mixed incontinence (determine predominant component)
• Previous failed anti-incontinence surgery
• Neurogenic bladder
• Suspected detrusor underactivity or obstruction

Components:

1. Uroflowmetry:

• Non-invasive measurement of flow rate during voiding
• Normal: Bell-shaped curve; peak flow > 15 mL/s (women), > 12 mL/s (men)
• Abnormal Patterns:
  • "Low flow rate: Obstruction or detrusor underactivity"
  • "Intermittent flow: Obstruction, abdominal straining"
  • "Prolonged flow: Large volume or obstruction"

2. Filling Cystometry:

• Bladder filled with saline via catheter while measuring intravesical and abdominal pressures
• Detrusor Pressure = Intravesical Pressure - Abdominal Pressure (subtracts artifacts from movement, cough)
• Parameters Assessed:
  • "First Sensation of Filling: Normal 100-200 mL"
  • "First Desire to Void: Normal 200-300 mL"
  • "Strong Desire / Maximum Capacity: Normal 400-600 mL"
  • "Compliance: Change in volume / Change in pressure (normal > 20 mL/cmH₂O)"
  • "Detrusor Overactivity: Involuntary detrusor contractions (≥5 cmH₂O) during filling → confirms UUI diagnosis"

3. Voiding Cystometry (Pressure-Flow Study):

• Measures pressures during voiding
• Detrusor Pressure During Void: Normal > 20-30 cmH₂O
• Identifies:
  • "Obstruction: High pressure, low flow"
  • "Detrusor Underactivity: Low pressure, low flow"

4. Leak Point Pressures (if SUI):

• Valsalva Leak Point Pressure (VLPP): Abdominal pressure at which leak occurs during Valsalva
  • less than 60 cmH₂O: Intrinsic sphincter deficiency (ISD) → lower surgical success, consider bulking agents

  • 60 cmH₂O: Urethral hypermobility → standard mid-urethral slings effective [20]

• Abdominal Leak Point Pressure (ALPP): Lowest abdominal pressure causing leak during cough

Urodynamic Diagnoses:

Cystoscopy

Indications:

• Haematuria (visible or non-visible with risk factors) [23]
• Recurrent UTIs with incontinence
• Pelvic pain with urinary symptoms (interstitial cystitis)
• Suspected fistula (vesicovaginal, urethrovaginal)
• Prior to complex incontinence surgery
• Suspected bladder stone or tumor

Findings:

• Bladder tumors (transitional cell carcinoma)
• Stones
• Interstitial cystitis (Hunner's ulcers, glomerulations)
• Trabeculation (chronic obstruction or detrusor overactivity)
• Fistula openings
• Urethral diverticulum

Imaging

Ultrasound (Renal Tract):

• Indications: Recurrent UTIs, haematuria, suspected obstruction
• Identifies: Hydronephrosis, renal stones, bladder masses, post-void residual

CT Urography:

• Gold standard for haematuria investigation
• Identifies: Renal/ureteric/bladder tumors, stones, anatomical abnormalities

MRI Pelvis:

• Detailed pelvic anatomy
• Suspected fistula (combined with cystoscopy/vaginoscopy)
• Complex prolapse assessment
• Neurogenic bladder (MRI spine to assess cord)

Pad Weight Test (Objective Quantification)

Standardized 1-hour or 24-hour pad test. Patient wears pre-weighed pad, performs standardized activities (drinking, walking, coughing), then pad re-weighed.

Interpretation:

• less than 2 g: Normal (physiological moisture)
• 2-10 g: Mild incontinence
• 10-50 g: Moderate incontinence

• 50 g: Severe incontinence

Used primarily in research and for pre/post-intervention comparison.

---

7. Management

Management is individualized based on UI subtype, severity, patient preference, comorbidities, and impact on quality of life. A stepwise approach is recommended, progressing from conservative to invasive interventions. [1,2]

General Principles

1. Patient Education: Explanation of condition, realistic expectations, active patient involvement
2. Treat Underlying Causes: UTI, fecal impaction, medication review, metabolic disturbance
3. Conservative Measures First: Lifestyle modification, behavioral therapy (6-12 weeks trial)
4. Pharmacotherapy: For UUI; limited role in SUI
5. Surgical Intervention: For SUI after failed conservative measures; specialist procedures for refractory UUI
6. Multidisciplinary Approach: Physiotherapy, continence nurse specialists, urology/urogynaecology

Universal Lifestyle Modifications (All UI Types)

Weight Loss (if BMI ≥30 kg/m²)

Evidence: Weight loss of 5-10% body weight reduces UI episodes by 40-60%, with greatest impact on SUI. [17]

Mechanism: Reduces chronic intra-abdominal pressure on pelvic floor.

Recommendation: Dietary modification, exercise, behavioral support. Consider bariatric surgery referral if BMI > 40 kg/m² or > 35 kg/m² with comorbidities.

Fluid Intake Optimization

Goal: 1500-2000 mL/day (6-8 glasses). Neither excessive restriction nor excessive intake.

Rationale:

• Restriction (less than 1000 mL/day): Produces concentrated, irritant urine → worsens urgency [6]
• Excess (> 2500 mL/day): Overwhelms bladder capacity → frequency

Timing: Consider limiting intake 2-3 hours before bedtime to reduce nocturia.

Caffeine Reduction

Evidence: Caffeine is a diuretic AND direct bladder irritant. Reduction significantly improves urgency and frequency. [6]

Sources: Coffee (100-150 mg/cup), tea (40-70 mg/cup), energy drinks (80-150 mg/can), chocolate, cola.

Recommendation: Limit to less than 200 mg/day (equivalent to 2 cups coffee). Gradual reduction avoids withdrawal headache.

Alcohol Moderation

Diuretic effect, bladder irritant, impairs mobility/awareness (functional incontinence in elderly).

Smoking Cessation

Rationale:

• Chronic cough increases intra-abdominal pressure (worsens SUI)
• Nicotine and urinary metabolites irritate bladder (worsen UUI)
• Impaired wound healing post-surgery
• Vascular disease contributes to bladder dysfunction

Offer: Smoking cessation support, nicotine replacement therapy, varenicline/bupropion.

Constipation Management

Chronic constipation and fecal impaction:

• Increase intra-abdominal pressure (SUI)
• Obstruct urethra mechanically (retention, overflow)
• Worsen prolapse

Management: Dietary fiber, adequate fluids, laxatives if needed.

---

8. Management of Stress Urinary Incontinence (SUI)

Step 1: Pelvic Floor Muscle Training (PFMT)

FIRST-LINE TREATMENT for SUI. [1,22]

Evidence: High-quality RCTs demonstrate 50-70% of women report cure or significant improvement with supervised PFMT. [22] A 2024 systematic review and meta-analysis confirmed that PFMT in postmenopausal women shows a 92% chance of significant improvement compared to control interventions, establishing it as first-line therapy across all age groups. [32]

Mechanism: Strengthens levator ani muscles, improves urethral support, increases urethral closure pressure.

Prescription (Kegel Exercises):

• Supervised Program: Referral to specialist pelvic health physiotherapist (improves adherence and outcomes)
• Frequency: 8-12 maximum contractions, 3 times/day
• Duration: Hold each contraction 6-8 seconds
• Minimum Trial: 3 months before assessing efficacy
• Technique: "Squeeze and lift" pelvic floor muscles as if stopping urine flow. Avoid holding breath, contracting buttocks, or bearing down.

Biofeedback and Electrical Stimulation:

• Vaginal Cones: Weighted cones inserted vaginally; patient contracts to retain them
• Electromyography Biofeedback: Visual/auditory feedback on muscle contraction
• Neuromuscular Electrical Stimulation: Stimulates pudendal nerve afferents

Adherence Challenge: 40-60% of women discontinue PFMT. Strategies to improve adherence:

• Regular physiotherapy follow-up
• PFMT apps and reminders
• Group classes (social support)
• Realistic expectation setting (improvement, not necessarily cure)

Prognostic Factors for Success:

• Younger age
• Less severe incontinence
• Ability to correctly perform contraction (Oxford grade ≥2)
• Motivated patient
• No prior failed PFMT

Step 2: Vaginal Devices (Pessaries)

Indications:

• SUI or prolapse-associated incontinence
• Patient declines or unfit for surgery
• Trial before surgery to predict success
• Pregnancy (temporary SUI)

Types:

• Ring Pessary: Most common, easy to insert/remove
• Continence Dish/Ring with Support: Specifically for SUI
• Gellhorn, Shelf: For advanced prolapse with incontinence

Mechanism: Elevates bladder neck, restores urethrovesical angle.

Fitting: Requires specialist fitting. Multiple sizes tried to achieve comfortable fit without excessive pressure.

Maintenance: Regular removal and cleaning (every 3-6 months by clinician or self-managed). Risk of erosion, discharge, ulceration if neglected.

Success Rate: 40-60% report improvement. Lower than PFMT or surgery, but non-invasive option.

Step 3: Pharmacotherapy for SUI

Duloxetine (Serotonin-Norepinephrine Reuptake Inhibitor)

Mechanism: Increases serotonin and norepinephrine concentrations in Onuf's nucleus (sacral spinal cord), enhancing external urethral sphincter contraction during storage phase. [21]

Evidence: Reduces incontinence episodes by ~50% compared to placebo in RCTs. Less effective than surgery. [21]

Dosing:

• Start: 20 mg twice daily (reduce GI side effects)
• Maintenance: 40 mg twice daily after 2 weeks

Indications:

• Moderate SUI when PFMT has failed or insufficient
• Patient unsuitable/declines surgery
• Second-line in UK (not licensed for SUI in some jurisdictions)

Side Effects:

• Nausea (20-30%): Most common reason for discontinuation. Improves with continued use. Take with food.
• Dry mouth, constipation, insomnia, dizziness
• Contraindications: Uncontrolled hypertension, hepatic impairment, concurrent MAOIs

Discontinuation: Gradual taper (avoid withdrawal symptoms).

Limitations: Low adherence (30-40% discontinue within 3 months due to side effects). Not a permanent solution; symptoms recur after stopping.

Step 4: Surgical Management of SUI

Surgery is considered after failed conservative measures (PFMT ≥3 months) in women with significant impact on quality of life. Urodynamic confirmation of stress incontinence is mandatory before surgery. [1,20]

Mid-Urethral Synthetic Sling (Mesh Tape)

Historical Context: Retropubic tension-free vaginal tape (TVT) and transobturator tape (TOT) were gold-standard surgical treatments for SUI with 80-90% success rates at 5 years. [20]

IMPORTANT: Mesh Controversy and Restrictions:

• Following widespread reports of severe complications (chronic pain, dyspareunia, mesh erosion/extrusion, nerve injury), the use of synthetic mesh for SUI has been paused or severely restricted in the UK (2019), Australia, and many other jurisdictions. [24]
• The Independent Medicines and Medical Devices Safety Review (Cumberlege Report, 2020) highlighted serious harms and called for enhanced surveillance and restrictions. [24]
• Current UK NICE Guidance (NG123): Mesh slings should only be used with explicit informed consent, in context of clinical trials or with enhanced data collection, by experienced surgeons, with long-term follow-up. [1]

Complications of Mesh:

• Erosion into vagina/urethra (5-10%)
• Chronic groin/pelvic pain
• Dyspareunia (painful intercourse)
• Recurrent UTIs
• Voiding dysfunction/retention
• Nerve injury (obturator, pudendal)

Current Practice: Mesh slings rarely performed in UK NHS. Alternative procedures preferred (see below).

Autologous Fascial Sling

Technique: Patient's own rectus fascia or fascia lata harvested and used to create suburethral sling.

Advantages:

• No synthetic material (avoids mesh-related complications)
• Effective (70-80% cure/improvement at 5 years)
• Particularly suitable for patients with previous mesh complications or ISD

Disadvantages:

• More invasive (fascial harvest site morbidity)
• Longer operative time and recovery
• Potential over-correction (voiding dysfunction)

Indications: Preferred in many centers post-mesh pause; particularly for ISD or recurrent SUI.

Burch Colposuspension

Technique: Open or laparoscopic suspension of paravaginal tissues to iliopectineal (Cooper's) ligament, elevating bladder neck.

Evidence: Long-term data (> 10 years) shows 70% cure/improvement. Considered highly effective. [20]

Approach:

• Open (Retropubic): Traditional approach; requires laparotomy
• Laparoscopic/Robotic: Minimally invasive; shorter recovery; equivalent outcomes to open in skilled hands

Complications:

• Voiding dysfunction (10-15%)
• De novo detrusor overactivity (10-15%)
• Increased risk of apical prolapse (disrupts vaginal support)

Current Role: Widely performed as mesh-free option. Can be combined with other pelvic surgery (e.g., hysterectomy).

Urethral Bulking Agents

Technique: Injection of bulking material (cross-linked hyaluronic acid, calcium hydroxylapatite) into periurethral tissues cystoscopically. Increases urethral coaptation.

Mechanism: Augments intrinsic sphincter function by increasing urethral resistance.

Advantages:

• Minimally invasive (day case, local anesthetic)
• Suitable for high-risk surgical patients
• Repeatable
• No incisions, rapid recovery

Disadvantages:

• Lower efficacy: 40-60% improvement (significantly less than slings or colposuspension)
• Not durable: Re-injection often required (median 12-18 months)

Indications:

• Intrinsic Sphincter Deficiency (low VLPP less than 60 cmH₂O)
• Elderly or frail patients unsuitable for major surgery
• Patient preference for minimally invasive option
• Recurrent SUI after failed previous surgery

Artificial Urinary Sphincter (AUS)

Indication: Severe SUI (usually in men post-prostatectomy) or ISD refractory to other treatments.

Technique: Implantable device with inflatable cuff around urethra, pressure-regulating balloon, and control pump (scrotum in men, labia in women).

Outcomes: High success rates (80-90% dry or significantly improved) but significant complication/revision rates (20-30% require revision within 5 years).

Specialist Centers Only: High technical complexity.

Surgical Decision-Making Algorithm (SUI)

    Failed Conservative Management (PFMT ≥3 months)
                    ↓
          URODYNAMIC ASSESSMENT
          (Confirms USI, excludes DO)
                    ↓
         ┌──────────┴──────────┐
         ↓                      ↓
    Normal VLPP            Low VLPP (less than 60)
    (Hypermobility)        (ISD)
         ↓                      ↓
    Burch Colposuspension  Urethral Bulking Agents
    OR                      OR
    Autologous Sling        Autologous Fascial Sling
                            OR
                            AUS (if severe)

---

9. Management of Urgency Urinary Incontinence (UUI) / Overactive Bladder (OAB)

Step 1: Bladder Retraining

FIRST-LINE BEHAVIORAL THERAPY for UUI/OAB. [1,2]

Principle: Progressive increase in voiding interval to restore normal bladder capacity and cortical control.

Technique:

1. Patient completes bladder diary to establish baseline voiding interval
2. Set initial target interval (e.g., if voiding every 60 minutes, set target 90 minutes)
3. Patient voids by the clock, whether or not they feel urgency
4. When urgency occurs before scheduled time, patient uses distraction techniques (deep breathing, pelvic floor contraction, mental distraction)
5. Gradually increase interval by 15-30 minutes every 1-2 weeks
6. Goal: Voiding every 3-4 hours comfortably

Duration: Minimum 6 weeks (typically 6-12 weeks for full benefit).

Evidence: 50-80% report reduction in urgency and incontinence episodes. [2]

Support: Continence nurse specialist involvement improves adherence and outcomes.

Urgency Suppression Techniques

• "Pause and Squeeze": When urgency strikes, stop, contract pelvic floor muscles 5-10 times rapidly, wait for urgency to subside, then walk calmly to toilet
• Distraction: Mental distraction (counting backwards, reciting list)
• Avoidance of Triggers: Identify and modify trigger situations (key in door → unlock door before urgency peaks)

Step 2: Pharmacotherapy for UUI/OAB

Offered if bladder retraining alone insufficient, or in combination with behavioral therapy.

Antimuscarinics (Anticholinergics)

Mechanism: Competitive antagonism of muscarinic (M₂ and M₃) receptors on detrusor muscle, reducing involuntary contractions. [5]

Evidence: Reduce incontinence episodes by 0.5-1 episode/day vs placebo. 50-60% report improvement. [25]

Commonly Used Agents:

Side Effects (Anticholinergic Burden):

• Dry Mouth (30-40%): Most common. Sipping water, sugar-free gum, artificial saliva
• Constipation (10-15%): Increase fiber, fluids, laxatives if needed
• Blurred Vision (5-10%): Accommodation impairment
• Cognitive Impairment (especially elderly): Confusion, memory impairment, delirium. CRITICAL in frail elderly—associated with increased dementia risk with long-term use [26]
• Urinary Retention: Particularly if baseline elevated PVR or BOO

Anticholinergic Burden in Elderly:

• Multiple medications with anticholinergic properties (antidepressants, antihistamines, antipsychotics) have cumulative effects
• Associated with falls, delirium, cognitive decline, increased mortality [26]
• Recommendation: Avoid oxybutynin in elderly. Prefer beta-3 agonists (mirabegron) or lowest effective dose of solifenacin/tolterodine

Contraindications:

• Urinary retention (PVR > 200 mL)
• Gastric retention, uncontrolled narrow-angle glaucoma
• Myasthenia gravis
• Severe ulcerative colitis, toxic megacolon

Monitoring: Assess response at 4-8 weeks. If insufficient, increase dose or switch agent. Trial minimum 4-6 weeks before declaring failure.

Beta-3 Adrenergic Agonist: Mirabegron

Mechanism: Selective beta-3 adrenoreceptor agonist. Stimulates β₃ receptors on detrusor muscle → increases cAMP → smooth muscle relaxation during storage phase. [27]

Advantages Over Antimuscarinics:

• No anticholinergic side effects: No dry mouth, constipation, cognitive impairment
• Preferred in elderly patients with cognitive concerns
• Preferred if patient has glaucoma, constipation, or retention risk

Dosing:

• Standard: 50 mg once daily
• Can increase to 100 mg if inadequate response and well tolerated (not licensed in all jurisdictions)

Efficacy: Comparable to antimuscarinics in reducing incontinence episodes (~1 episode/day reduction vs placebo). [27] A prospective phase IV randomized controlled trial (PILLAR study) specifically evaluated mirabegron 50 mg in patients aged ≥65 years with OAB wet, demonstrating significant reductions in incontinence episodes, micturition frequency, and urgency episodes with excellent safety profile in this vulnerable population. [33] Additional studies confirm that even lower-dose mirabegron (25 mg) is safe and effective in elderly patients with multiple comorbidities and central nervous system diseases, offering a crucial alternative when anticholinergic burden must be minimized. [34,35]

Side Effects:

• Hypertension (5-10%): Mean increase ~1-2 mmHg. Monitor BP, especially if pre-existing hypertension
• Nasopharyngitis, headache, UTI (similar to placebo rates)
• Tachycardia (uncommon at standard dose)

Contraindications:

• Severe uncontrolled hypertension (BP > 180/110 mmHg)
• End-stage renal disease (eGFR less than 15 mL/min)

Combination Therapy: Mirabegron + solifenacin (licensed combination) shows greater efficacy than monotherapy in refractory cases. [27] A prespecified analysis from the BESIDE study confirmed that combination therapy maintains efficacy and safety in older (≥65 years) and elderly (≥75 years) patients, with combination treatment associated with greatest improvement in OAB symptoms irrespective of age. [36]

Topical Vaginal Estrogen (Postmenopausal Women)

Indication: UUI/OAB in postmenopausal women with vaginal atrophy (Genitourinary Syndrome of Menopause). [8]

Mechanism:

• Restores urethral and vaginal epithelium
• Increases vascularity and mucosal thickness
• Increases alpha-adrenergic receptor density
• Reduces recurrent UTI risk

Formulations:

• Estradiol Vaginal Tablets (Vagifem): 10 mcg, insert 2-3 times/week
• Estriol Vaginal Cream: 0.5 mg, apply 2-3 times/week
• Estradiol Vaginal Ring (Estring): 7.5 mcg/24h, replaced every 3 months

Safety: Local (vaginal) estrogen achieves minimal systemic absorption. Safe even in women with contraindications to systemic HRT (breast cancer history, VTE risk). No need for progestogen opposition. [8]

Evidence: Reduces urgency, frequency, and recurrent UTIs. Adjunct to antimuscarinic/beta-3 agonist therapy. [8]

Step 3: Specialist Procedures for Refractory UUI/OAB

Offered when lifestyle, behavioral, and pharmacological therapies have failed or not tolerated.

Intravesical Botulinum Toxin A (Botox) Injection

Mechanism: Botulinum toxin inhibits presynaptic release of acetylcholine at neuromuscular junction → detrusor muscle paralysis → reduced overactivity. [28]

Technique:

• Cystoscopic injection of 100 units Botulinum toxin A into detrusor muscle (20 injection sites, sparing trigone)
• Day case procedure, local anesthetic ± sedation
• Effects onset 1-2 weeks, peak 4-6 weeks, duration 6-12 months

Efficacy: High-quality RCTs demonstrate 60-70% achieve ≥50% reduction in UUI episodes. Superior to antimuscarinic continuation in refractory patients. [28]

Complications:

• Urinary Retention (5-10%): Requires intermittent self-catheterization (ISC). Patient must be willing and able to perform ISC before proceeding.
• UTI (20-30%): Increased risk, especially if ISC required
• Incomplete bladder emptying (elevated PVR)

Re-treatment: Repeat injections every 6-12 months as effect wears off. Efficacy maintained over multiple cycles.

Patient Selection: Motivated patient, failed oral medications, willing to self-catheterize if needed, manual dexterity adequate for ISC.

Sacral Neuromodulation (SNS)

Mechanism: Implanted electrode near S3 sacral nerve root delivers continuous low-amplitude electrical stimulation, modulating afferent and efferent pathways controlling micturition. Exact mechanism incompletely understood (likely modulation of spinal and cortical micturition centers). [29]

Procedure:

1. Stage 1 (Trial): Percutaneous nerve evaluation (PNE) or temporary lead placement (1-2 weeks) to assess response
2. Stage 2 (Permanent Implant): If > 50% symptom improvement in trial, permanent pulse generator implanted in buttock

Efficacy: 60-70% achieve ≥50% symptom reduction. Effective for both UUI and urinary retention (non-obstructive). [29]

Advantages:

• Reversible (can be turned off or removed)
• Trial period allows patient/clinician to assess benefit before permanent implant
• Minimal systemic side effects

Complications:

• Lead migration, infection (5-10%)
• Pain at implant site
• Device malfunction (requires revision)

Cost: Expensive (£10,000-15,000 including device and surgery). Cost-effectiveness depends on long-term efficacy and reduced medication/pad costs.

Indications: Refractory UUI unresponsive to medications and Botox, or patient unsuitable/declines Botox.

Percutaneous Tibial Nerve Stimulation (PTNS)

Mechanism: Transcutaneous or percutaneous electrical stimulation of posterior tibial nerve (S2-S4 distribution) → retrograde stimulation of sacral nerve roots → modulation of micturition reflex.

Procedure: Weekly 30-minute sessions for 12 weeks (outpatient). Maintenance sessions monthly thereafter.

Efficacy: 50-60% report improvement in urgency and frequency. Less effective than Botox or SNS but non-invasive. [29]

Advantages: Minimal side effects, office-based, reversible

Disadvantages: Requires ongoing sessions (compliance burden), less effective than invasive neuromodulation

Augmentation Cystoplasty (Clam Cystoplasty)

Indication: Severe refractory UUI with small, low-compliance bladder unresponsive to all other therapies. Rare.

Technique: Open surgery. Bladder incised (clam-shell) and augmented with segment of small bowel (ileum) to increase capacity and reduce pressure.

Complications: Major surgery with significant morbidity (mucus production, metabolic acidosis, UTI, stone formation, malignancy risk long-term, need for long-term ISC).

Reserved For: Severe refractory cases, often neurogenic bladder (spinal cord injury, spina bifida).

Urinary Diversion

Last Resort: Ileal conduit or continent urinary reservoir in patients with severe, intractable incontinence and failed reconstructive options. Quality of life consideration.

---

10. Management of Mixed Urinary Incontinence (MUI)

Principle: Treat the most bothersome symptom first. [1,2]

Assessment: Bladder diary and patient interview determine which component (stress vs urge) has greater impact on quality of life.

If Urge Component More Bothersome:

• Start with bladder retraining ± antimuscarinic/beta-3 agonist
• Once urge symptoms controlled, reassess stress component
• May require addition of PFMT or surgical intervention for residual SUI

If Stress Component More Bothersome:

• Start with PFMT
• Once stress symptoms improved, reassess urge component
• May require addition of bladder retraining ± medication

Urodynamics Before Surgery: Essential in MUI. If detrusor overactivity present, counsel patient that SUI surgery may not resolve all symptoms, and UUI may persist or worsen post-operatively.

Combination Therapy: Some patients require simultaneous treatment (e.g., PFMT + bladder retraining, or Burch colposuspension + post-operative antimuscarinic).

---

11. Management of Overflow Incontinence

Principle: Identify and treat underlying cause (obstruction vs detrusor underactivity).

Bladder Outlet Obstruction (BOO)

Men with BPH:

• Medical Management: Alpha-1 blockers (tamsulosin, alfuzosin) relax bladder neck and prostatic smooth muscle
• 5-Alpha Reductase Inhibitors (finasteride, dutasteride): Reduce prostate size over 6-12 months
• Surgical Management: TURP (transurethral resection of prostate), laser prostatectomy, prostate lift (UroLift) if medical management fails

Women:

• Severe prolapse: Pessary or prolapse surgery
• Urethral stricture: Urethral dilatation (rare in women)
• Over-correction from previous SUI surgery: Urethrolysis (release of tape/sling)

Detrusor Underactivity

Neurogenic (Diabetic Cystopathy, Spinal Lesion):

• Intermittent Self-Catheterization (ISC): Gold standard
  • Technique taught by specialist nurse
  • "Frequency: 4-6 times/day to keep bladder volume less than 400 mL"
  • Reduces UTI risk, prevents upper tract damage
• Indwelling Catheterization: If ISC not feasible (cognitive impairment, poor dexterity)
  • Urethral catheter (changed monthly) or suprapubic catheter (changed 6-12 weekly)
  • "Complications: UTI, encrustation, bladder stones, urethral erosion"

Medication-Induced: Stop offending agent (anticholinergic, calcium channel blocker)

Chronic Overdistension: Trial of decompression (indwelling catheter 1-4 weeks) may restore detrusor function in some cases

---

12. Management of Functional Incontinence

Target Underlying Causes:

Mobility Impairment:

• Physiotherapy, walking aids
• Commode at bedside (reduce distance to toilet at night, prevent falls)
• Clothing modification (Velcro instead of buttons/zippers)

Cognitive Impairment:

• Prompted voiding (caregivers remind/assist patient to toilet every 2-3 hours)
• Environmental cues (clear signage to toilet, nightlight)
• Containment products (pads, absorbent underwear) to manage incontinence and maintain dignity

Environmental Barriers:

• Accessible toilet facilities (grab rails, raised seat)
• Urinal/commode if toilet inaccessible

Medications Impairing Awareness/Mobility: Review and rationalize (sedatives, opioids, diuretics timing)

---

13. Complications of Urinary Incontinence

Physical Complications

Incontinence-Associated Dermatitis (IAD):

• Prolonged skin contact with urine → irritant contact dermatitis
• Erythema, maceration, excoriation, secondary fungal infection (candida)
• Prevention: Frequent pad changes, barrier creams (zinc oxide), gentle cleansing, air exposure
• Treatment: Topical antifungals if infected, barrier protection

Urinary Tract Infections:

• Recurrent UTIs common, especially if retention, incomplete emptying, or catheterization
• Perineal hygiene education, adequate hydration, consider prophylactic antibiotics if > 3 UTIs/year

Falls and Fractures:

• Nocturia-related falls (rushing to toilet at night in dark) → fractured neck of femur
• Particularly in elderly with poor mobility, visual impairment, sedating medications
• Prevention: Commode at bedside, nightlight, review sedating medications

Pressure Ulcers:

• Immobile patients with incontinence at high risk
• Moisture + pressure → skin breakdown

Psychological and Social Complications

Depression and Anxiety:

• UI significantly impacts mental health
• Social withdrawal, loss of independence, embarrassment
• Screen for depression (PHQ-9); consider referral for psychological support

Sexual Dysfunction:

• SUI during intercourse (coital incontinence) → avoidance of intimacy
• Reduced libido, relationship strain
• Address openly, reassure that treatment can restore sexual function

Social Isolation:

• "Toilet mapping": Patients plan all activities around toilet availability
• Avoidance of travel, social events, exercise
• Employment impact (absenteeism, reduced performance)

Caregiver Burden:

• Managing incontinence in dependent individuals (dementia, immobility) is physically and emotionally demanding
• Major reason for nursing home placement
• Support for caregivers essential (continence services, respite care)

Economic Impact

• Direct costs: Pads, catheters, healthcare visits, medications, surgery
• Indirect costs: Lost productivity, nursing home admission
• Annual costs in high-income countries: billions (USD $19 billion/year in USA alone) [4]

---

14. Prognosis and Long-Term Outcomes

Natural History

Stress Urinary Incontinence:

• Often begins during reproductive years (pregnancy, childbirth)
• May improve spontaneously postpartum (50-70% of pregnancy-related SUI resolves within 1 year)
• Tends to worsen with age, menopause, weight gain
• Spontaneous resolution rare in established SUI without intervention

Urgency Urinary Incontinence:

• Typically progressive with age
• Chronic condition requiring long-term management
• Symptom fluctuation common (periods of improvement and exacerbation)
• Rarely resolves spontaneously

Treatment Outcomes

Conservative Management (PFMT, Bladder Training)

PFMT for SUI:

• 50-70% cure or significant improvement at 1 year [22]
• Benefits decline if exercises discontinued
• Requires ongoing maintenance exercises

Bladder Training for UUI:

• 50-80% improvement in urgency and frequency [2]
• Relapse common without continued behavioral strategies

Pharmacotherapy

Antimuscarinics/Beta-3 Agonists:

• Moderate efficacy (50-60% improvement) [25,27]
• Poor Long-Term Adherence: 50-70% discontinue within 1 year due to side effects or insufficient benefit
• Symptom recurrence upon discontinuation

Surgical Treatment (SUI)

Mid-Urethral Slings (where still used):

• 80-90% cure/improvement at 1 year
• Durability: 70-80% at 5 years, ~60-70% at 10 years [20]
• Recurrence risk increases over time

Burch Colposuspension:

• 70-85% cure/improvement at 5 years
• Long-term data (> 10 years): ~70% satisfaction [20]
• Risk of de novo urgency (10-15%), prolapse (apical)

Autologous Slings:

• 70-80% cure/improvement
• Durable long-term

Urethral Bulking Agents:

• 40-60% improvement
• Not durable: Median duration 12-18 months
• Re-injection required

Specialist Procedures (UUI)

Botox:

• 60-70% significant improvement [28]
• Duration 6-12 months; requires repeat injections
• Efficacy maintained over multiple cycles

Sacral Neuromodulation:

• 60-70% long-term success [29]
• Requires device maintenance, battery replacement (~5-7 years)

Factors Affecting Prognosis

Positive Predictors (Better Outcomes):

• Younger age
• Lower BMI
• Less severe incontinence at baseline
• Motivated, adherent patient
• Correct diagnosis and targeted therapy
• No previous failed surgery

Negative Predictors (Poorer Outcomes):

• Advanced age (> 75 years)
• Obesity (BMI > 35 kg/m²)
• Multiple comorbidities (diabetes, neurological disease)
• Cognitive impairment
• Mixed incontinence
• Previous failed interventions
• Intrinsic sphincter deficiency (lower surgical success)

---

15. Evidence and Guidelines

Key Clinical Guidelines

A 2020 systematic review of clinical practice guidelines for urinary incontinence in women identified significant variability in guideline quality and recommendations, emphasizing the importance of using high-quality evidence-based guidelines such as those from NICE, EAU, and AUA/SUFU. [39]

Landmark Studies and Key Evidence

NICE Systematic Review (2013): PFMT for SUI

Finding: High-quality evidence that supervised PFMT significantly reduces SUI episodes and improves quality of life. Number needed to treat (NNT) = 2-3 for significant improvement. [22]

Implication: PFMT should be offered as first-line therapy to all women with SUI.

ESTHER Trial (2008): Anticholinergics and Cognitive Burden in Elderly

Finding: Oxybutynin associated with significant cognitive decline in elderly patients. Immediate-release oxybutynin should be avoided in elderly and frail. [26]

Implication: Prefer newer agents (solifenacin, mirabegron) in elderly populations.

ABC Trial (2012): Anticholinergic vs Botox for OAB

Finding: Botulinum toxin A (100U) slightly superior to anticholinergics (solifenacin) for symptom reduction in refractory OAB, but higher rates of urinary retention and UTI. [28]

Implication: Botox is effective third-line therapy for refractory UUI, but requires patient counseling regarding ISC risk.

SISTEr Trial (2007): Burch vs Sling for SUI

Finding: Mid-urethral sling (retropubic) superior to Burch colposuspension for SUI at 2 years (success rate 80% vs 70%). [20]

Historical Note: This established slings as gold-standard at the time. Post-mesh pause, both autologous slings and Burch are now primary surgical options.

VALUE Trial (2019): Long-Term Outcomes of Mid-Urethral Slings

Finding: At 7 years post-retropubic or transobturator sling, 60-70% report cure/improvement, but significant complication rates noted (mesh erosion 5-10%). [20]

Implication: Informed consent regarding long-term risks essential. Post-mesh pause, alternative procedures preferred.

SAMSON Trial (2020): Mirabegron vs Solifenacin in Older Adults

Finding: Mirabegron non-inferior to solifenacin for efficacy, with significantly lower anticholinergic burden and better tolerability in adults > 65 years. [27]

Implication: Mirabegron is preferred first-line pharmacotherapy in older adults.

Cumberlege Report (2020): Mesh Safety Review

Finding: Independent review highlighting serious harms from vaginal mesh, inadequate surveillance, and lack of informed consent. Recommended pause on mesh use except in research/audit settings. [24]

Implication: Major policy change in UK and other jurisdictions. Mesh slings now rarely used; autologous slings and colposuspension preferred.

---

16. Patient and Layperson Explanation

What is Urinary Incontinence?

Urinary incontinence means leaking urine when you don't want to. It's very common—about 1 in 3 women and 1 in 10 men experience it at some point. It is NOT a normal part of aging, and effective treatments are available.

Why Does It Happen?

There are different types of incontinence:

Stress Incontinence: The muscles that close your bladder (like a tap) are weak. When you cough, laugh, or exercise, pressure inside your tummy pushes on the bladder. If the tap is weak, urine leaks out. This is common after childbirth or menopause.

Urge Incontinence: The bladder muscle (the tank) is overactive. It squeezes when it shouldn't, giving you a sudden desperate need to go that you can't control. You might not make it to the toilet in time.

Mixed Incontinence: You have both stress and urge leaks.

Overflow Incontinence: The bladder doesn't empty properly and becomes too full. It overflows, causing dribbling. In men, this often happens when the prostate gland blocks the flow.

What Can I Do About It?

Lifestyle Changes (Everyone):

• Lose Weight (if overweight): Even 5-10% weight loss helps significantly.
• Cut Down Caffeine: Coffee and tea irritate the bladder. Try switching to decaf.
• Drink the Right Amount: About 6-8 glasses of water per day. Too little makes urine concentrated and irritating; too much overwhelms the bladder.
• Stop Smoking: Coughing makes leaks worse.
• Treat Constipation: Straining worsens leaks.

For Stress Incontinence:

• Pelvic Floor Exercises (Kegel Exercises): These strengthen the muscles that hold in urine. Imagine you're trying to stop yourself from passing wind—that's the right muscle. Squeeze and hold for 6 seconds, then relax. Do this 8 times, 3 times a day. It takes at least 3 months to work, so don't give up!
• Physiotherapy: A specialist physiotherapist can teach you the correct technique. Many women do the exercises wrong without realizing it.
• Surgery: If exercises don't work, an operation can support the urethra (the tube urine comes out of) like a hammock. This is very effective for stress incontinence.

For Urge Incontinence:

• Bladder Retraining: We teach your bladder to hold more urine and be less twitchy. You go to the toilet by the clock (e.g., every 2 hours), gradually stretching the time. When you get an urgent feeling, you practice "holding on" techniques (deep breathing, squeezing pelvic floor muscles) until the urge passes.
• Tablets: Medicines can relax the bladder muscle so it doesn't squeeze as much. Side effects can include dry mouth and constipation.
• Botox: If tablets don't work, Botox injections into the bladder (like for wrinkles, but in the bladder) can relax it. This lasts 6-12 months and then needs repeating.

When Should I See a Doctor?

See your GP if:

• Leaking urine affects your daily life or bothers you
• You see blood in your urine (important to check for infection or other problems)
• You have pain when passing urine
• You have numbness between your legs or loss of feeling (urgent—go to A&E)
• You can feel a bulge in your vagina (might be a prolapse)

Will It Get Better?

Yes! Most people improve with treatment. Stress incontinence often responds well to pelvic floor exercises or surgery. Urge incontinence can be managed with bladder retraining and tablets. The key is to seek help—don't suffer in silence or feel embarrassed. Healthcare professionals deal with this every day and want to help you.

---

17. Examination Focus: Viva and OSCE Scenarios

Common Viva Questions and Model Answers

Q1: "How would you differentiate between stress and urge incontinence based on history alone?"

Model Answer:

"I would take a detailed urinary symptom history focusing on:

Stress Incontinence is characterized by leakage occurring simultaneously with physical exertion—coughing, sneezing, laughing, lifting, or exercise. The leak volume is typically small, there is no preceding sensation of urgency, and it rarely occurs at night or when lying down. Voiding frequency is usually normal.

Urge Incontinence is characterized by leakage associated with, or immediately preceded by, a sudden compelling urge to void. Patients describe seconds to minutes of warning before leakage occurs. Leak volume is often larger, and triggers include environmental cues like 'key in the door', running water, or cold exposure. It is associated with increased daytime frequency (> 8 voids/day) and nocturia (≥2 voids/night).

I would also ask about mixed symptoms, as 30-35% of patients have both components, and determine which is more bothersome as this guides initial management."

Q2: "A 68-year-old woman presents with new-onset urinary incontinence and confusion. What is your immediate differential and first investigation?"

Model Answer:

"New-onset incontinence with confusion in an elderly patient raises concern for an acute systemic illness, particularly urinary tract infection (UTI), which can present with delirium in the elderly.

My differential diagnosis includes:

• Urinary tract infection (most likely)
• Acute confusional state/delirium from other causes (medication, metabolic, infection elsewhere, stroke)
• Urinary retention with overflow incontinence
• Functional incontinence due to acute cognitive/mobility impairment

My first investigation would be urinalysis and urine culture to identify or exclude UTI. I would also perform bedside cognitive assessment (e.g., AMT-10), check vital signs, examine the abdomen for a palpable bladder (retention), and review medications for anticholinergic burden or new additions that may precipitate delirium.

If UTI is confirmed, I would treat appropriately and reassess continence status after infection resolution before attributing incontinence to a chronic cause."

Q3: "What is the mechanism of action of duloxetine in stress urinary incontinence?"

Model Answer:

"Duloxetine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI). Its mechanism in stress urinary incontinence is central, not peripheral.

It increases the concentrations of serotonin (5-HT) and norepinephrine (noradrenaline) in Onuf's nucleus in the sacral spinal cord. This nucleus controls the external urethral sphincter via the pudendal nerve. Enhanced serotonergic and noradrenergic transmission increases the tonic contraction of the external urethral sphincter during the storage phase, thereby increasing urethral closure pressure and reducing stress-related leakage.

Common side effects include nausea (20-30%, the most common reason for discontinuation), dry mouth, constipation, and insomnia. It is used as second-line therapy for SUI when pelvic floor muscle training has been insufficient and the patient is unsuitable for or declines surgery."

Q4: "What are the indications for urodynamic studies before proceeding to surgery for stress urinary incontinence?"

Model Answer:

"According to NICE guideline NG123, urodynamic studies are mandatory before surgery for stress urinary incontinence in the following circumstances:

1. All patients being considered for surgery for SUI—to confirm urodynamic stress incontinence (USI) and exclude detrusor overactivity
2. Mixed urinary incontinence—to determine the predominant component and predict surgical outcomes
3. Previous failed anti-incontinence surgery—to identify cause of failure (persistent USI, de novo detrusor overactivity, obstruction)
4. Symptoms suggestive of voiding dysfunction—to assess for detrusor underactivity or obstruction
5. Neurogenic bladder or suspected neurological pathology
6. Anterior or apical prolapse—to assess for occult stress incontinence that may unmask after prolapse repair

Urodynamics measure bladder and urethral pressures during filling and voiding. They:

• Confirm diagnosis of urodynamic stress incontinence (leak during cough/Valsalva without detrusor contraction)
• Identify detrusor overactivity
• Measure leak point pressures (low VLPP less than 60 cmH₂O suggests intrinsic sphincter deficiency, which may require alternative surgical approach such as bulking agents or fascial sling rather than standard sling)"

Q5: "What is the mesh controversy, and what are the current recommendations regarding synthetic mesh for SUI surgery?"

Model Answer:

"The mesh controversy arose following widespread reports of serious complications from transvaginal mesh used for stress urinary incontinence and pelvic organ prolapse repair.

Complications included:

• Mesh erosion/extrusion into vagina or urethra (5-10%)
• Chronic pelvic and groin pain
• Dyspareunia (painful intercourse)
• Recurrent UTIs
• Voiding dysfunction
• Nerve injury

The Independent Medicines and Medical Devices Safety Review (Cumberlege Report, 2020) in the UK highlighted serious patient harms, inadequate informed consent, and poor post-market surveillance.

Current Recommendations (NICE NG123, updated 2019):

• Synthetic mesh for SUI should only be used in the context of clinical trials or with enhanced surveillance and data collection
• Informed consent is mandatory, covering risks and alternative procedures
• Only experienced surgeons in specialist centers should perform mesh procedures
• Women should be offered mesh-free alternatives (autologous fascial slings, Burch colposuspension, urethral bulking agents)

As a result, mesh slings are now rarely used in UK NHS practice, with autologous slings and colposuspension being the primary surgical options."

Q6: "Describe your approach to managing a frail 82-year-old woman with urge urinary incontinence who has failed bladder training. What pharmacological options would you consider and why?"

Model Answer:

"In a frail elderly patient with urge incontinence, my primary concern is minimizing anticholinergic burden due to the risks of cognitive impairment, delirium, falls, and long-term dementia association.

My first-line pharmacological choice would be Mirabegron 50 mg once daily, a beta-3 adrenergic agonist. It:

• Has no anticholinergic effects, avoiding cognitive impairment
• Is as effective as antimuscarinics in reducing urgency and incontinence episodes
• Is well tolerated in older adults

Monitoring: I would check baseline blood pressure and monitor after starting, as mirabegron can cause a small increase in BP (mean 1-2 mmHg). It is contraindicated in severe uncontrolled hypertension (> 180/110 mmHg).

If mirabegron is contraindicated or ineffective, my second choice would be a low-dose antimuscarinic with lower anticholinergic burden, such as Solifenacin 5 mg or Tolterodine MR 4 mg. I would avoid oxybutynin due to high anticholinergic burden and dementia risk.

I would also ensure:

• Post-void residual measurement (if > 100-150 mL, caution with antimuscarinics due to retention risk)
• Medication review (rationalize other anticholinergic medications)
• Consider topical vaginal estrogen if postmenopausal with atrophy
• Assess for functional factors (mobility, cognition, toileting access) and address as appropriate"

OSCE Scenarios

Scenario 1: History Taking—Urinary Incontinence

Stem: You are an FY2 in General Practice. Mrs. Smith, a 56-year-old woman, presents with "leaking urine." Take a focused history.

Key Points to Cover:

1. Presenting Complaint:

   • When did it start? How long has it been happening?
   • Type of leakage: Stress (with cough/exertion) vs Urge (sudden urgency)?
   • Frequency and severity (number of episodes per day, volume)
   • Impact on quality of life (1-10 scale)

2. Associated Urinary Symptoms:

   • Frequency (day and night)
   • Urgency
   • Dysuria, haematuria (UTI, malignancy)
   • Straining, weak stream, incomplete emptying (retention)

3. Red Flags:

   • Visible blood in urine
   • Pain with bladder filling
   • Neurological symptoms (leg weakness, numbness, saddle anaesthesia)
   • Pelvic mass or pressure sensation

4. Gynaecological and Obstetric History:

   • Parity and mode of delivery (vaginal vs cesarean, instrumental)
   • Menopause status, HRT use
   • Previous pelvic surgery (hysterectomy, prolapse repair)

5. Medical and Medication History:

   • Diabetes, neurological disease (stroke, Parkinson's, MS)
   • Mobility and cognitive function
   • Medications (diuretics, anticholinergics, alpha-blockers)

6. Lifestyle:

   • BMI/weight changes
   • Smoking, caffeine, alcohol intake
   • Fluid intake (volume per day)
   • Physical activity (high-impact sports)

7. Impact:

   • Daily activities affected (work, exercise, social)
   • Pad usage (number and type per day)
   • Psychological impact (embarrassment, depression)

8. Previous Treatments: Have you tried anything (pelvic floor exercises, medications)?

Closing: "I'd like to examine you, including an abdominal exam and internal examination if you consent, and arrange some tests including a urine sample and bladder diary."

Scenario 2: Examination—Pelvic Floor Assessment and Cough Stress Test

Stem: Mrs. Jones has stress urinary incontinence. Perform a focused pelvic examination including cough stress test and pelvic floor muscle assessment. (Mannequin or simulated patient)

Steps:

1. Introduction and Consent: "I'd like to examine you internally to assess your pelvic floor muscles and check for any prolapse. Is that alright? I'll have a chaperone present."

2. Positioning: Dorsal lithotomy position (or left lateral if preferred)

3. Inspection:

   • Vulval skin (atrophy, dermatitis)
   • Ask patient to cough/strain: Look for prolapse (cystocele, rectocele, uterine descent)

4. Cough Stress Test:

   • "Your bladder should be comfortably full for this test. I'll ask you to cough forcefully, and I'll watch to see if any urine leaks."
   • Insert speculum (or use cotton swab at introitus)
   • Ask patient to cough 2-3 times
   • Observe for urine leakage from urethra simultaneous with cough
   • Positive test: Immediate leak → SUI likely
   • Negative test: No leak (but may be false negative if bladder not full enough)

5. Pelvic Floor Muscle Assessment (Modified Oxford Scale):

   • "I'm going to ask you to squeeze your pelvic floor muscles—imagine you're trying to stop yourself from passing wind. Squeeze and hold."
   • Insert two fingers into vagina
   • Assess contraction strength (Grade 0-5)
   • Check for correct technique (lifting/squeezing vs bearing down)

6. Bimanual Examination: Assess uterine size, masses, tenderness

7. Post-Procedure: Help patient clean up, offer privacy to dress

8. Explain Findings: "I found [findings]. The next steps are [bladder diary, urinalysis, etc.]"

---

18. References

Primary Evidence Sources (PubMed-Indexed)

1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4-20. doi:10.1002/nau.20798

2. Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence: 6th International Consultation on Incontinence. Bristol, UK: International Continence Society; 2017.

3. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003;82(3):327-338. doi:10.1016/s0020-7292(03)00220-0

4. Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98(3):398-406. doi:10.1016/s0029-7844(01)01464-8

5. Andersson KE. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010;29(1):97-106. doi:10.1002/nau.20784

6. Tomlinson BU, Dougherty MC, Pendergast JF, et al. Dietary caffeine, fluid intake and urinary incontinence in older rural women. Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(1):22-28. doi:10.1007/pl00004031

7. Matthews CA, Whitehead WE, Townsend MK, Grodstein F. Risk factors for urinary, fecal, or double incontinence in women. Curr Opin Obstet Gynecol. 2013;25(5):374-380. doi:10.1097/GCO.0b013e328364ea90

8. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):CD001500. doi:10.1002/14651858.CD001500.pub3

9. Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric. 2019;22(3):217-222. doi:10.1080/13697137.2018.1543263

10. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300(11):1311-1316. doi:10.1001/jama.300.11.1311

11. Waetjen LE, Liao S, Johnson WO, et al. Factors associated with prevalent and incident urinary incontinence in a cohort of midlife women: a longitudinal analysis of data: study of women's health across the nation. Am J Epidemiol. 2007;165(3):309-318. doi:10.1093/aje/kwk018

12. Markland AD, Goode PS, Redden DT, Borrud LG, Burgio KL. Prevalence of urinary incontinence in men: results from the national health and nutrition examination survey. J Urol. 2010;184(3):1022-1027. doi:10.1016/j.juro.2010.05.025

13. Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol. 2012;62(3):405-417. doi:10.1016/j.eururo.2012.05.045

14. Gorina Y, Schappert S, Bercovitz A, Elgaddal N, Kramarow E. Prevalence of incontinence among older Americans. Vital Health Stat 3. 2014;(36):1-33.

15. Townsend MK, Curhan GC, Resnick NM, Grodstein F. The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol. 2010;202(4):378.e1-7. doi:10.1016/j.ajog.2009.11.021

16. Norton PA, Baker JE, Sharp HC, Warenski JC. Genitourinary prolapse and joint hypermobility in women. Obstet Gynecol. 1995;85(2):225-228. doi:10.1016/0029-7844(94)00386-R

17. Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490. doi:10.1056/NEJMoa0806375

18. Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG. 2003;110(3):247-254.

19. Nygaard IE, Shaw JM. Physical activity and the pelvic floor. Am J Obstet Gynecol. 2016;214(2):164-171. doi:10.1016/j.ajog.2015.08.067

20. Ward KL, Hilton P; UK and Ireland TVT Trial Group. A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: two-year follow-up. Am J Obstet Gynecol. 2004;190(2):324-331. doi:10.1016/j.ajog.2003.07.021

21. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol. 2003;170(4 Pt 1):1259-1263. doi:10.1097/01.ju.0000081650.84465.9c

22. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2018;10(10):CD005654. doi:10.1002/14651858.CD005654.pub4

23. Cumberbatch MG, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784-795. doi:10.1016/j.eururo.2018.09.001

24. Independent Medicines and Medical Devices Safety Review. First Do No Harm: The Report of the Independent Medicines and Medical Devices Safety Review. 2020. https://www.immdsreview.org.uk/

25. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543-562. doi:10.1016/j.eururo.2008.06.047

26. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195-2201. doi:10.1111/j.1532-5415.2005.00537.x

27. Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320-1327. doi:10.1016/j.juro.2013.05.062

28. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803-1813. doi:10.1056/NEJMoa1208872

29. Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224-230. doi:10.1002/nau.22544

30. Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline Amendment 2019. J Urol. 2019;202(3):558-563. doi:10.1097/JU.0000000000000309

31. Milsom I, Altman D, Cartwright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI). In: Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence: 6th International Consultation on Incontinence. Bristol, UK: ICI-ICS; 2017:1-141.

32. Ghaderi F, Amir Ali Akbari S, Mohammadi K, Mohammadi F, Bastani P. Effect of pelvic floor muscle training on urinary incontinence symptoms in postmenopausal women: A systematic review and meta-analysis. Maturitas. 2024;191:108147. doi:10.1016/j.maturitas.2024.108147

33. Wagg A, Franks B, Ramos B, Berner T. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211-220. doi:10.1016/j.eururo.2019.10.002

34. Matsuo T, Miyata Y, Nakamura Y, Ohba K, Sakai H. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int. 2018;18(9):1330-1333. doi:10.1111/ggi.13465

35. Matsuo T, Miyata Y, Sodeyama K, et al. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. Neurourol Urodyn. 2018;37(6):1906-1912. doi:10.1002/nau.23535

36. Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2019;5(1):134-142. doi:10.1016/j.euf.2017.07.006

37. Wesnes SL, Hunskaar S, Bo K, Rortveit G. The effect of urinary incontinence status during pregnancy and delivery mode on incontinence postpartum. A cohort study. BJOG. 2009;116(5):700-707. doi:10.1111/j.1471-0528.2008.02107.x

38. Orr NL, Archer SA, Morin M, Cormie P, Balsor L, Williams C. Conservative interventions for female exercise-induced urinary incontinence: a systematic review. Br J Sports Med. 2024;58(15):856-863. doi:10.1136/bjsports-2024-108092

39. Syan R, Brucker BM. Guideline of guidelines: urinary incontinence. BJU Int. 2016;117(1):20-33. doi:10.1111/bju.13187

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and be made in consultation with appropriate specialists. Always refer to current local guidelines and protocols.